KEDW (Epigenetic Bioregulator)

KEDW (Lys-Glu-Asp-Trp) is a synthetic tetrapeptide bioregulator investigated for its broad epigenetic effects across multiple tissues, including chromatin remodeling, multi-organ gene expression modulation, and epigenetic aging reversal.

KEDW (Lys-Glu-Asp-Trp) is a synthetic tetrapeptide from the Khavinson bioregulatory peptide series, distinguished by its broad multi-tissue epigenetic activity. While most Khavinson tetrapeptides exhibit tissue-preferential effects, KEDW has been investigated for its capacity to modulate chromatin structure and gene expression across multiple organ systems simultaneously.

Overview

Epigenetic aging is characterized by progressive changes in DNA methylation, histone modification, and chromatin architecture that accumulate across all tissues with age. These changes lead to silencing of genes required for tissue maintenance and inappropriate activation of inflammatory and senescence-associated genes. The epigenetic clock concept, established by Horvath (2013), demonstrated that DNA methylation patterns track biological age across multiple tissues with remarkable consistency.

KEDW's multi-tissue epigenetic activity positions it within this framework as a potential modulator of systemic epigenetic drift. Unlike tissue-specific bioregulators such as Cardiogen (heart), Bronchogen (lung), or Pinealon (brain), KEDW has been studied for effects across multiple tissue types, suggesting it may interact with chromatin regions that are commonly accessible across diverse cell types.

Mechanism of Action

KEDW's mechanism operates within the bioregulatory peptide framework described by Khavinson (2002), with particular emphasis on chromatin-level effects.

Chromatin Remodeling: Khavinson et al. (2004) demonstrated that short peptides including those with similar structural properties to KEDW can induce decondensation of heterochromatin in lymphocytes from elderly subjects. The tryptophan residue in KEDW's sequence is notable, as tryptophan's indole ring system is known to intercalate with DNA structures, potentially enhancing chromatin-remodeling capacity. Lezhava et al. (2006) extended these findings to show reactivation of silenced chromatin regions in aging cells treated with bioregulatory peptides.

Multi-Gene Expression Modulation: The charged amino acid composition of KEDW (two acidic residues: Glu, Asp; one basic: Lys; plus aromatic Trp) provides a physicochemical profile suited for interaction with DNA minor groove regions across multiple gene promoters. Khavinson et al. (2009) characterized how short peptide sequences interact with DNA in a sequence-specific manner, with binding affinity determined by the peptide's charge distribution and aromatic character.

Epigenetic Reprogramming: KEDW's broad-spectrum activity suggests it may target chromatin modifications common to aging across tissues — such as age-related increases in heterochromatin at previously active gene loci, or dysregulation of histone acetylation patterns. This positions KEDW as a potential epigenetic reprogramming agent operating at the chromatin accessibility level.

Reconstitution Calculator

Reconstitution Calculator

Calculate your peptide dosing

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Peptide Bioregulation and Lifespan

Khavinson and Anisimov (2003) reviewed evidence that bioregulatory peptides can extend lifespan in experimental models, an effect attributed to normalization of gene expression across multiple aging organ systems. This systemic anti-aging effect is most consistent with peptides that have multi-tissue activity, positioning KEDW within the class of broadly acting epigenetic bioregulators.

Chromatin Structure in Aging

Khavinson et al. (2004) established that bioregulatory peptides can reverse age-related chromatin condensation in human lymphocytes. Elderly subjects showed significantly increased heterochromatin, and peptide treatment restored chromatin accessibility toward patterns observed in younger individuals. This foundational work demonstrates the principle that short peptides can modulate the epigenetic state of aging cells, the core mechanism proposed for KEDW's multi-tissue activity.

Gene Expression Across Tissues

Anisimov et al. (2004) used microarray analysis to characterize how short peptides alter gene expression across functionally diverse gene families including apoptosis regulation, stress response, signal transduction, and matrix maintenance. The breadth of gene expression changes observed supports the concept of chromatin-level modulation affecting multiple downstream pathways simultaneously — the proposed mode of action for a multi-tissue epigenetic bioregulator like KEDW.

Short Peptide-DNA Binding Specificity

Khavinson et al. (2009) provided molecular-level evidence for sequence-specific binding of short peptides to double-stranded DNA. The study demonstrated that peptides interact with the DNA minor groove, with binding characteristics determined by the peptide's amino acid composition. KEDW's combination of charged and aromatic residues gives it a distinct DNA-binding profile that may account for its broader tissue activity compared to peptides with more restricted binding preferences.

Safety Profile

KEDW has been investigated in preclinical models within the Khavinson bioregulatory peptide research program with no significant adverse effects reported. As a short tetrapeptide composed of natural amino acids (Lys, Glu, Asp, Trp), it is expected to undergo rapid enzymatic degradation to constituent amino acids. The multi-tissue nature of KEDW's activity raises theoretical questions about off-target gene expression effects, though no adverse consequences have been reported in available literature. Formal toxicology studies meeting international regulatory standards have not been published. The natural amino acid composition and low molecular weight suggest minimal immunogenicity risk.

Pharmacokinetic Profile

Half-life
Not established

Quick Start

Route
Subcutaneous injection

Molecular Structure

Molecular Properties
Formula
C₂₃H₃₁N₅O₈
CAS
Not established

Research Protocols

subcutaneous Injection

Administered via subcutaneous injection.

Quality Indicators

What to look for

  • Multiple peer-reviewed studies available

Frequently Asked Questions

References (9)

  1. [2]
    Khavinson VK, Anisimov VN Peptide bioregulation of aging Bull Exp Biol Med (2003)
  2. [7]
  3. [8]
    Khavinson VK et al Peptides and Aging Int J Mol Sci (2020)
  4. [6]
    Khavinson VK et al Mechanisms of biological activity of short peptides Bull Exp Biol Med (2009)
  5. [3]
    Khavinson VK, Lezhava TA, Malinin VV Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med (2004)
  6. [1]
    Khavinson VK Peptides and Ageing Neuro Endocrinol Lett (2002)
  7. [4]
  8. [5]
  9. [9]
Updated 2026-03-08Reviewed by Tides Research Team9 citationsSources: peptide-wiki-mdx, peptide-wiki-mdx-v2

On this page